|
ASTRONOMER
Aortic Stenosis progression Observation: Measuring Effects of Rosuvastatin
Ongoing trial
 |
Author(s) |
Chan K-L, Teo K, Tam J, Dumesnil JG |
 |
Title(s) |
Rationale, design, and baseline characteristics of a randomized trial to assess the effect of cholesterol lowering on the progression of aortic stenosis: The Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial |
|
Reference(s) |
Am Heart J 2007;153:925–31 |
|
Disease |
Aortic stenosis |
|
Purpose |
To assess the effect of cholesterol reduction with rosuvastatin on the progression of aortic stenosis in patients with mild to moderate aortic stenosis |
|
Study design |
Randomised, double-blind, placebo-controlled |
|
Follow-up |
Aim 3–5 years |
|
Patients |
272 patients, aged 18–82 years, with maximal aortic valve velocity 2.5–4.0 m/s by continuous wave Doppler and LDL cholesterol within target level according to the Canadian Guidelines |
|
Treatment regimen |
Rosuvastatin, 40 mg/day, or placebo |
|
Results |
Not yet available |
|
|
|
